Clinical trial NCT01491633 (phase 2, status: terminated)
Conditions: squamous cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Reason stopped: 
    safety issues/concerns per df/hcc pi
  
Eligibility criteria:

        Inclusion Criteria:

          -  Stage III/B or IV squamous NSCLC

          -  Measurable disease

          -  Previously offered all standard chemotherapy regimens for advanced squamous cell lung
             cancer

          -  ECOG performance status of 0 or 1

          -  Estimated life expectancy greater than 12 weeks

          -  Normal organ and marrow function

          -  Confirmed availability of archival pathology samples

          -  Agrees to discontinue St. Johns Wort

          -  Able to take medications by mouth

          -  Willing and able to use acceptable method of birth control for the entire study period
             and for at least 4 weeks after the last dose of study drug

        Exclusion Criteria:

          -  Pregnant or breast-feeding

          -  Chemotherapy or radiotherapy within 4 weeks prior to entering study

          -  Receiving any other investigational agents

          -  Known untreated or progressive brain metastases

          -  History of prior treatment with or allergic reactions attributed to compounds of
             similar chemical or biologic composition to dasatinib, nilotinib or imatinib

          -  Taking medications known to be potent CYP3A4 inhibitors

          -  Currently taking H2 inhibitors or proton pump inhibitors

          -  Currently taking drugs or have taken drugs in the past 7 days that are generally
             accepted to have a risk of causing Torsades de Pointes

          -  HIV positive

          -  Clinically uncontrolled hypertension (blood pressure > 160/110)

          -  Previous or concurrent malignancy except adequately treated basal or squamous cell
             skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively,
             and without evidence of recurrence for at least 5 years

          -  Active and uncontrolled clinically significant infection

          -  Chronic gastrointestinal disease

          -  Acquired or congenital bleeding disorder or clinically significant gastrointestinal
             bleeding within 3 months

          -  Supplemental oxygen required for current malignancy

          -  Evidence of symptomatic pleural effusions unless undergoing a therapeutic
             thoracentesis as part of non-study care

          -  Individuals who are prisoners or who are compulsory detained for medical or
             psychiatric reasons

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Hypokalemia or hypomagnesemia that cannot be corrected prior to dasatinib
             administration